Latest: FDA Approves New Biosimilar for Oncology Treatment

RAINBOWFISH Study in NEJM Highlights Risdiplam’s Impact in Presymptomatic SMA, Importance of Newborn Screening

0 Mins
Phase 3 study demonstrates risdiplam's effectiveness in treating presymptomatic spinal muscular atrophy, showing improved outcomes for infants identified through newborn screening.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago